Advertisement
![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
Document › Details
Imperial Innovations Group plc. (9/21/16). "Press Release: Innovations Invests £5.1m in Artios Pharma Limited".
Imperial Innovations Group plc (AIM: IVO, 'the Group', 'Innovations') has committed £5.1 million to the £25.0 million Series A funding round of Artios Pharma Ltd. ('Artios' or 'the Company') a new Cambridge-based private biotech company launched today, focused on the development of novel DNA Damage Response (DDR) cancer therapies.
Artios was formed with assets out of Cancer Research Technology (CRT), the technology transfer unit of Cancer Research UK (CRUK). The Company is led by Dr. Niall Martin, Artios' Chief Executive Officer, who has proven expertise in DDR drug discovery as previous Director of Drug Discovery at KuDOS Pharmaceuticals, which discovered Olaparib (an FDA-approved targeted therapy for cancer). KuDOS was sold to AstraZeneca in January 2006 for $210m. Prior to joining Artios, Dr. Martin was a co-founder and Chief Operating Officer at MISSION Therapeutics, another Cambridge-based drug discovery company in which Innovations has invested.
Artios is backed by a strong syndicate of leading European and US life science investors including SV Life Sciences, Merck Ventures, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures in addition to Innovations. The investment will be used to build a high value pipeline of DDR therapies sourced from Cancer Research UK and global collaborators, and to progress its lead programmes, including Pol-theta, into the clinic.
Following this investment Innovations will hold a 14.9% interest in the Company.
Bobby Soni, Director of Healthcare Ventures at Imperial Innovations commented:
"It's not every day that you get an opportunity to help launch such an exciting company.
"Targeting the DNA Damage Response is an exciting and promising field of biology. DDR drug products have generated considerable interest following the recent clinical successes of PARP inhibitors which have highlighted the potential for DDR drugs to cause selective death in cancer cells.
"We are delighted to be part of such an impressive syndicate of investors which reflects Artios' international ambitions to build a pipeline of first-in-class DDR therapies identified from a network of global, independent collaborators."
Media Queries
For media enquiries regarding our portfolio of companies, press releases or any aspect of Imperial Innovations’ business, please contact Jon Davies or Gavin Reed.
Jon Davies
Director of Communications
jon.davies@imperialinnovations.co.uk Telephone 020 3727 2044
Gavin Reed
Marketing Assistant
gavin.reed@imperialinnovations.co.uk Telephone 0203 053 8820
Record changed: 2017-01-05 |
Advertisement

More documents for Touchstone Innovations (Group)
- [1] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...
- [2] Imperial Innovations Group plc. (2/4/16). "Press Release: Result of Placing [Not for United States, Australia, Canada or Japan or any other jurisdiction in which unlawful] "....
- [3] Dyer, Renae [Digital Look]. (2/4/16). "News: Imperial Innovations Proposes £100m Fundraising"....
- [4] Apollo Therapeutics Fund. (1/25/16). "Press Release: Apollo Therapeutics. Consortium of World-Leading UK Universities and Global Pharmaceutical Companies Launch £40 Million Fund to Drive Therapeutic Innovation". London....
- [5] Auspherix Ltd.. (6/3/15). "Press Release: Auspherix Raises £6 Million to Progress Its Novel Antibiotics and Establishes UK Operations". Stevenage....
- [6] PsiOxus Therapeutics Ltd.. (5/19/15). "Press Release: PsiOxus Therapeutics Raises a £25m Series C Investment to Progress Oncolytic Virus plus Checkpoint Inhibitor Combination Study in Metastatic Colorectal Cancer". Oxford, UK....
- [7] Crescendo Biologics Ltd.. (12/17/13). "Press Release: Crescendo Biologics Raises £17.5M ($28M) in Series A Financing". Cambridge....
- [8] Imperial Innovations Group plc. (11/20/13). "Press Release: Pulmocide Receives £17m Series A Funding"....
- [9] PolyTherics Ltd.. (9/9/13). "Press Release: PolyTherics Appoints Julian Smith as Chief Financial Officer". London....
- [10] Imperial Innovations Group plc. (12/6/11). "Press Release: £8 Million Funding for New Start-up TopiVert"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top